This site requires JavaScript and cookies to be enabled.

Qelbree offers
full-day exposure1,2

A Qelbree 200 mg capsule contains two distinct types of beads: immediate-release (IR) beads and extended-release (ER) beads, providing 24-hour patient exposure.
A Qelbree 200 mg capsule contains two distinct types of beads: immediate-release (IR) beads and extended-release (ER) beads, providing 24-hour patient exposure.

The first 2-bead Microtrol® technology delivery of nonstimulant viloxazine for
24-hour exposure1,2

  • Microtrol utilizes rapid- and
    extended-release technology

Qelbree offers full
24-hour exposure in a once-daily dose1,2

Microtrol is a rapid- and extended-release platform.2

A line graph illustrates the mean viloxazine plasma concentration over a 24-hour period following a once-daily (QD) dose of Qelbree utilizing the Microtrol® rapid- and extended-release platform. The concentration curve rapidly rises within the first few hours post-dose, plateaus between 4 and 7 hours with a median of 5 hours, and steadily declines through Hour 24, with a note indicating the time to reach steady state (SS) is 2 days.
  • Duration of exposure that lasts throughout the day2
  • Demonstrated gradual release of an ER formulation2
  • Median half-life 7.02 ± (4.74 hours)1
Smiling younger woman hugging a smiling older woman from behind in a kitchen.
A young woman smiles while hugging an older woman from behind in a kitchen.

Qelbree shows no evidence of abuse potential

Minimized risk of treatment abuse, misuse, or diversion1,3-6

Viloxazine was found to be free of drug dependence in an animal model of abuse liability.4

No withdrawal symptoms or signs of dependence were reported as AEs during human clinical trials.2

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AE, adverse event; ER, extended release; QD, once daily; SS, steady state; Tmax, time to maximum plasma concentration.

Discover more:

Qelbree dosing  Access and support  FAQs 

What I find patients like most about Qelbree is its once-daily dosing with all-day coverage.

– Derek Susalla, PA-C

Watch their video

Stay informed

Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.

Sign up 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Data on file, Supernus Pharmaceuticals, Inc.
3. Key prescription stimulant label updates. U.S. Food and Drug Administration. May 11, 2023. Accessed June 25, 2026. https://www.fda.gov/media/168050/download
4. Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12(1):155-161. doi:10.1016/0091-3057(80)90430-x
5. Kurtz SP, Buttram ME, Margolin ZR, Wogenstahl K. The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017. Pharmacoepidemiol Drug Saf. 2019;28(5):700-706. doi:10.1002/pds.4771
6. Viloxazine street prices, May 27, 2025. StreetRx website. Accessed February 6, 2026. https://streetrx.com.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.